The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry

Simple item page
dc.contributor.authorUslu, Sadettin
dc.contributor.authorCan, Gerçek
dc.contributor.authorŞenel, Soner
dc.contributor.authorİnanç, Nevsun
dc.contributor.authorAkar, Servet
dc.contributor.authorKocaer, Sinem Burcu
dc.contributor.authorBirlik, Merih
dc.contributor.authorÇapar, Sedat
dc.contributor.authorAkkoç, Nurullah
dc.contributor.authorÖnen, Fatoş
dc.contributor.buuauthorDalkılıç, Ediz
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Romatoloji Bilim Dalı.tr_TR
dc.date.accessioned2024-01-09T12:29:32Z
dc.date.available2024-01-09T12:29:32Z
dc.date.issued2018-06
dc.descriptionBu çalışma, 13-16 Haziran 2018 tarihlerinde Amsterdan[Hollanda]’da düzenlenen Congress of the European-League-Against-Rheumatism (EULAR) Kongresi‘nde bildiri olarak sunulmuştur.tr_TR
dc.description.sponsorshipEuropean League Against Rheumatismen_US
dc.identifier.citationUslu, S. vd. (2018). ''The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry''. Annals of the Rheumatic Diseases, 77(Supplement 2), 329-329.en_US
dc.identifier.endpage329tr_TR
dc.identifier.issn0003-4967
dc.identifier.issn1468-2060
dc.identifier.issueSupplement 2en_US
dc.identifier.startpage329tr_TR
dc.identifier.urihttps://doi.org/10.1136/annrheumdis-2018-eular.6440
dc.identifier.urihttps://ard.bmj.com/content/77/Suppl_2/329
dc.identifier.urihttps://hdl.handle.net/11452/38904
dc.identifier.volume77tr_TR
dc.identifier.wos000444351001026tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.wosSCIE
dc.indexed.wosCPCIS
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalAnnals of the Rheumatic Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRheumatologyen_US
dc.subject.wosRheumatologyen_US
dc.titleThe efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registryen_US
dc.typeArticleen_US
dc.wos.quartileQ1 (Rheumatology)en_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dalkılıç_vd_2018.pdf
Size:
168.82 KB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science